What happened
On October 15, 2026, shares of AbbVie, Eli Lilly and Gilead Sciences closed within 1% of their 52‑week highs after a broad technology sell‑off that began on Monday. AbbVie rose 2.1% to $165.30, Eli Lilly gained 1.9% to $950.20 and Gilead climbed 1.6% to $85.10, lifting the pharma sector index by 1.8% on the day.
Why it matters
The rally signals a classic risk‑off rotation from high‑growth tech stocks to defensive healthcare names, which can tighten financing conditions for biotech startups while boosting cash flow for established drug makers. Investors are reallocating capital toward sectors with stable cash generation, potentially reshaping M&A activity and R&D spending in the pharmaceutical industry.
Your next move — for a otherWatch for similar risk‑off patterns in other defensive sectors such as utilities and consumer staples, and adjust your personal investment risk model accordingly. Use the pharma rally as a case study for how macro‑economic shocks can quickly shift market leadership.
Read full article ↗